Clinical trial
Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA…
NCT00293839 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00293839 |
|---|---|
| Title | Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder |
| Official title | Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Urinary Incontinence |
| Intervention type | Drug |
| Interventions | oxybutynin chloride |
| Enrollment | 790 |
| Completion | Dec 1, 2002 |
| First posted | Feb 20, 2006 |
| Last update posted | Feb 3, 2025 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: